ArticlePathogens (Basel, Switzerland)2022
Genome Analysis of ESBL-Producing
Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Multidrug-resistant Escherichia coli ST940 carrying blaMolecular biology reports · 2026Article
- Emergence of Escherichia coli Hybrid Pathotype ETEC/STEC: A Macroepidemiological Approach of Molecular Characterization in the United States Swine Population.Transboundary and emerging diseases · 2026Article
- Genomic insight into the antibiotic-resistant determinants ofFrontiers in microbiology · 2026Article
- Molecular characterization of multidrug-resistant Escherichia coli in the Greater Accra Region, Ghana: a 'One Health' approach.One health outlook · 2025Article
- Mechanisms ofInternational journal of molecular sciences · 2025Article
- Occurrence of Extended-spectrum β-lactamase (ESBL) and Carbapenemase-producing Escherichia coli isolated from Childhood Diarrhoea in Yaoundé, Cameroon.BMC microbiology · 2024Article
- A NovelAntibiotics (Basel, Switzerland) · 2024Article
- Genomic characterization of multi drug resistant ESBL-producing Escherichia coli isolates from patients and patient environments in a teaching hospital in Ghana.BMC microbiology · 2024Article
- Article
- Whole-Genome Sequencing of Human and PorcineAntibiotics (Basel, Switzerland) · 2024Article
- Anthropogenic contamination sources drive differences in antimicrobial-resistantApplied and environmental microbiology · 2024Article
- Article
- Wastewater and environmental sampling holds potential for antimicrobial resistance surveillance in food-producing animals - a pilot study in South African abattoirs.Frontiers in veterinary science · 2024Article
- Escherichia ruysiae May Serve as a Reservoir of Antibiotic Resistance Genes across Multiple Settings and Regions.Microbiology spectrum · 2023Article
- Antimicrobial Resistance and Clonal Lineages ofAntibiotics (Basel, Switzerland) · 2023Review
- Whole genome sequencing and characteristics of extended-spectrum beta-lactamase producingFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The resistome, virulome and mobilome of extended spectrum ß-lactamase (ESBL)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.